Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 14/20 | 0.55 |
| ▸ | HTR2A | P28223 | 4/20 | 0.40 |
| ▸ | HTR2C | P28335 | 4/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18912167 | 0.84 | GRIN2B (0.52) | GRIN2BHTR2AHTR2CNPY5R | |
| SCHEMBL18911985 | 0.83 | HTR2A (0.46) | GRIN2BHTR2AHTR2CNPY5RGRIN1 | |
| SCHEMBL21936469 | 0.81 | GRIN2B (0.55) | GRIN2BHTR2AHTR2CGRIN1KCNH2 | |
| SCHEMBL18911988 | 0.81 | NPY5R (0.43) | GRIN2BHTR2AHTR2CNPY5RKDM4E | |
| SCHEMBL21872476 | 0.79 | HTR2C (0.46) | GRIN2BHTR2AHTR2C | |
| SCHEMBL21872463 | 0.78 | HTR2C (0.43) | GRIN2BHTR2AHTR2CNPY5RGRIN1 | |
| SCHEMBL18911807 | 0.78 | HTR2A (0.43) | GRIN2BHTR2AHTR2C | |
| SCHEMBL10165388 | 0.78 | HTR2A (0.50) | GRIN2BHTR2AHTR2C | |
| SCHEMBL21872944 | 0.77 | HTR2C (0.46) | GRIN2BHTR2AHTR2CNPY5RGRIN1 | |
| SCHEMBL21936470 | 0.77 | HTR2C (0.44) | GRIN2BHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883766-B2 | Ion channel modulators and methods of use | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-11 | — | — | US | disclosed |
| US-20120208790-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-16 | — | — | US | disclosed |
| US-8193194-B2 | Ion channel modulators and methods of use | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208790-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | CACNA1G, CACNA1C, CACNA1B | GRIN2B 213/4885HTR2A 720/4885HTR2C 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.